| 產(chǎn)品編號 | bs-12422R-Cy3 |
| 英文名稱1 | Rabbit Anti-14-3-3 sigma/MKRN3/Cy3 Conjugated antibody |
| 中文名稱 | Cy3標記的14-3-3σ抗體 |
| 別 名 | 14 3 3 protein sigma; 14-3-3 protein sigma; 1433S_HUMAN; Epithelial cell marker protein 1; Er; HME 1; HME1; MGC143283; Mkrn3; Mme1; OTTHUMP00000004242; RP23 137L22.11; SFN; SFN protein; Stratifin; YWHAS. |
| 規(guī)格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 研究領域 | 細胞生物 染色質(zhì)和核信號 神經(jīng)生物學 信號轉導 干細胞 轉錄調(diào)節(jié)因子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human, Rat, (predicted: Mouse, Dog, Pig, Horse, Rabbit, Sheep, ) |
| 產(chǎn)品應用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 28kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human 14-3-3 sigma |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: 14-3-3 proteins regulate many cellular processes relevant to cancer biology, notably apoptosis, mitogenic signaling and cell-cycle checkpoints. Seven isoforms, denoted 14-3-3 b, g, e, z, h, q and s, comprise this family of signaling intermediates. 14-3-3 s, also known as SFN, stratifin, HME1 or YWHAS, is a secreted adaptor protein that is involved in regulating both general and specific signaling pathways. Expressed predominately in stratified squamous keratinising epithelium, 14-3-3 s is able to bind and modify the activity of a large number of proteins, such as KRT17 (Keratin 17), through recognition of a phosphothreonine or phosphoserine motif. When bound to Keratin 17, for example, 14-3-3 s acts to stimulate the Akt/mTOR signaling pathway by upregulating protein synthesis and cell growth. 14-3-3 s also functions to positively mediate IGF-I-induced cell cycle progression and can bind to a variety of translation initiation factors, thus controlling mitotic translation. In response to tumor growth, 14-3-3 s positively regulates the tumor suppressor p53 and increases the rate of p53-regulated inhibition of G2/M cell cycle progression. Multiple isoforms of 14-3-3 s exist due to alternative splicing events. Function: Adapter protein implicated in the regulation of a large spectrum of both general and specialized signaling pathways. Binds to a large number of partners, usually by recognition of a phosphoserine or phosphothreonine motif. Binding generally results in the modulation of the activity of the binding partner. When bound to KRT17, regulates protein synthesis and epithelial cell growth by stimulating Akt/mTOR pathway. p53-regulated inhibitor of G2/M progression. Subunit: Homodimer. Interacts with KRT17 and SAMSN1 (By similarity). Found in a complex with XPO7, EIF4A1, ARHGAP1, VPS26A, VPS29, VPS35 and SFN. Interacts with GAB2. Interacts with SRPK2. Interacts with COPS6. Interacts with RFWD2; this interaction leads to proteasomal degradation. Subcellular Location: Cytoplasm. Nucleus. Secreted. May be secreted by a non-classical secretory pathway. Tissue Specificity: Present mainly in tissues enriched in stratified squamous keratinizing epithelium. Similarity: Belongs to the 14-3-3 family. Database links: Entrez Gene: 2810 Human Entrez Gene: 55948 Mouse Omim: 601290 Human SwissProt: P31947 Human SwissProt: O70456 Mouse Unigene: 523718 Human Unigene: 44482 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
